United States
Lixte Biotechnology (Nasdaq: LIXT) is a biotechnology company founded in 2004 and based in the United States. The company is focused on developing drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds to target them in animal models. The company's current drug portfolio includes inhibitors of protein phosphatases critical to cell division and DNA damage repair, as well as inhibitors of protein deacetylases regulating pathways of gene expression and protein degradation.
The phosphatase inhibitors have shown potential to enhance the effectiveness of cytotoxic anti-cancer drugs and radiation therapy, making them useful for the treatment of various cancers in combination with existing standard chemotherapy regimens and personalized cancer medicine. Lixte's lead compound LB-100 is in Phase I trial and has the potential to be first-in-class.
Additionally, the deacetylase inhibitors have demonstrated anti-cancer activity and the ability to correct enzyme deficiencies underlying inborn metabolic diseases. Lixte's drug development strategy has led to the discovery of novel compounds with potential therapeutic applications in other important diseases, including reducing tissue damage following stroke, heart attack, and septic shock, as well as addressing neurodegenerative diseases, traumatic brain injury, and fungal dermatitis.
The company received a Post-IPO Equity investment on 12 April 2022. Lixte Biotechnology's innovative approach and promising drug portfolio position it as a key player in the advancement of cancer treatment and the potential treatment of other related diseases, attracting interest from investors in the healthcare and pharmaceutical sectors.
